Oseltamivir resistance during treatment of H7N9 infection

@article{Hay2013OseltamivirRD,
  title={Oseltamivir resistance during treatment of H7N9 infection},
  author={Alan J. Hay and Frederick G. Hayden},
  journal={The Lancet},
  year={2013},
  volume={381},
  pages={2230-2232}
}
2230 www.thelancet.com Vol 381 June 29, 2013 Detection of an Arg292Lys mutation (N2 numbering) in the virus neuraminidase (NA) gene within 2 days of initiating oseltamivir treatment, in the fi rst reported human infection by avian A(H7N9) infl uenza virus, raised concern about emergence of resistance during treat ment with neuraminidase inhibitors. This is impor tant because a Ser31Asn resistance mutation in the M2 protein of A(H7N9) viruses, also present in A(H1N1)pdm09 and seasonal A(H3N2… Expand
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses
TLDR
It is demonstrated that R292K, E119V, and I222K reduced the inhibitory activity of oseltamivir, not only in the NI assay, but also in infected ferrets, judged particularly by viral loads in nasal washes, and may signal the need for alternative therapeutics. Expand
Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
TLDR
In mice, oral administration of BXM was completely protected from a lethal A/Anhui/1/2013 (H7N9) challenge, and reduced virus titers more than 2–3 log in the lungs, and the potent therapeutic effects of BXA in mice were still observed when a higher virus dose was administered or treatment was delayed up to 48 hours post infection. Expand
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment
TLDR
It is reported that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro and this would allow a rapid regulatory approval process for this drug under pandemic threat. Expand
Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
TLDR
The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Expand
Anti-H7N9 avian influenza A virus activity of interferon in pseudostratified human airway epithelium cell cultures
TLDR
Both rhIFN-α2b and rhIFn-λ1 had antiviral activity against H7N9, and this protection was related to the induction of ISGs. Expand
H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs
TLDR
The H7N9 virus is a reassortant virus containing internal genes from the H9N2 virus and previously described mammalian adaption markers which could allow the virus to adapt efficiently to a mammalian host. Expand
Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F(ab′)2
TLDR
In vivo assays suggested that 600U of the preparations could efficiently protect BALB/c mice from a lethal dose of A/Anhui/01/2013 (H7N9) infection even when administered two days post infection, suggesting this highly purified preparation should be a potential candidate for treating severe patients suffering from influenza A H7n9. Expand
Identification of NMS‐873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses
  • Jiantao Zhang, Yanmei Hu, +5 authors J. Wang
  • Medicine, Biology
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2019
TLDR
The results suggest that p97 could be a novel antiviral target and its inhibitor, NMS‐873, is a promising antiviral drug candidate. Expand
Zoonotic Influenza and Human Health—Part 2: Clinical Features, Diagnosis, Treatment, and Prevention Strategies
TLDR
Armed with robust diagnostic modalities, antiviral medications, vaccines, and advanced surveillance systems, the world is today better prepared to face a new influenza pandemic and to limit the burden of zoonotic influenza than ever before. Expand
Epidemiology, Evolution, and Pathogenesis of H7N9 Influenza Viruses in Five Epidemic Waves since 2013 in China.
TLDR
The different waves of H7N9 regarding their epidemiology, pathogenesis, evolution, and characteristic features are summarized and compared, and factors behind the recent increase in the number of human cases and sudden outbreaks in chickens are speculated on. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
TLDR
Sensitivity testing to oseltamivir carboxylate revealed that the neuraminidases of viruses that have an Arg292Lys, Glu119Val, or Asn294Ser mutation were about 10(4)-10(5)-fold, 500-fold, or 300-fold more resistant than their pretreatment neuraminIDases, respectively. Expand
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
TLDR
It is suggested that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents. Expand
Determinants of antiviral effectiveness in influenza virus A subtype H5N1.
TLDR
Oseltamivir is especially effective for treating H5N1 infection when given early and before onset of respiratory failure, and the effect of viral clade on fatality and treatment response deserves further investigation. Expand
Poor responses to oseltamivir treatment in a patient with influenza A (H7N9) virus infection
TLDR
This case calls for increased awareness of potential resistance of H7N9 to oseltamivir, which is the recommended choice of treatment, after a 56-year-old male patient was presented with fever and cough and swab specimens of this patient were still positive for H7n9. Expand
Efficacy of Oseltamivir Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus
TLDR
Early oseltamivir treatment is crucial for protection against highly pathogenic H5N1 viruses and the higher dose may be needed for the treatment of more virulent viruses. Expand
Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.
  • J. Louie, Samuel Yang, +5 authors T. Uyeki
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
NAI treatment of critically ill pH1N1 patients improves survival, while earlier treatment conveyed the most benefit, patients who started treatment up to 5 days after symptom onset also were more likely to survive. Expand
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance
TLDR
The emergence of antiviral resistance in A/H7N9 viruses, especially in patients receiving corticosteroid therapy, is concerning, needs to be closely monitored, and considered in pandemic preparedness planning. Expand
Adjunctive therapies and immunomodulatory agents in the management of severe influenza
TLDR
The efficacy of agents with potential immunomodulating effects, including intravenous immunoglobulin, N-acetylcysteine, acute use of statins, macrolides, peroxisome proliferator-activated receptors agonists, celecoxib and mesalazine, and the role of plasmapheresis and hemoperfusion as rescue therapy, deserve more investigation and where feasible, studies by RCTs. Expand
Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.
TLDR
Oseltamivir significantly reduces mortality when started up to 6-8 days after symptom onset and appears to benefit all age groups. Expand
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
TLDR
The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect. Expand
...
1
2
3
...